Boston Scientific Moves Aggressively on Stent Graft

Under a series of agreements recently announced, Boston Scientific (Natick, MA, USA) has exclusive distribution rights to a new percutaneous stent graft and is to make an investment in the company that developed the stent graft. Moreover, it has an exclusive option to acquire that company, which is TriVascular, Inc. (Santa Rosa, CA, USA). Terms of the agreements were not disclosed.

The stent graft is designed to improve the outcome of abdominal aortic aneurysm (AAA) therapy by being more durable and being deployed through the skin. The stent graft is delivered by a catheter small enough to allow a doctor to make a small puncture in the leg instead of an incision. TriVascular reduced the delivery system size by eliminating much of the metal required to keep other stent grafts open and replacing the metal with a polymer that is injected into channels within the graft during the procedure.

"We believe that TriVascular is the first to have developed a solution that substantially decreases the profile of the device down to a percutaneous range while also enhancing the durability of the graft,” said Paul La Violette, senior vice president and president, cardiovascular, Boston Scientific.





Related Links:
Boston Scientific
TriVascular